PD-1 Inhibitor Plus GP as Neoadjuvant Therapy for Locoregionally Advanced Nasopharyngeal Carcinoma

NCT05340270 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

150

Enrollment

OTHER

Sponsor class

Conditions

Nasopharyngeal Carcinoma
Neoadjuvant Therapy
PD-1 Inhibitor

Interventions

DRUG: PD-1 inhibitor+GP
DRUG: GP

Sponsor

Guangxi Medical University

Collaborators

[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]